Gain Therapeutics, Inc. (GANX): R&D Expense
$10.21M
Year ended 2025-12-31
$10.10M
Trailing 12 months to 2026-06-30
+6.8%
3-year compound annual growth
+35.2%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $10.21M | -5.4% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $10.79M | -6.3% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $11.52M | +37.5% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $8.38M | +16.9% | 2024-03-26, From 2022-01-01 |
| 2021-12-31 | $7.16M | +217.1% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $2.26M | n/a | 2022-03-25, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Gain Therapeutics, Inc. (GANX) | 2025-12-31 | $10.21M | -5.4% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $21.82M | +16.1% |
| Moleculin Biotech, Inc. (MBRX) | 2025-12-31 | $15.89M | -10.4% |
| BriaCell Therapeutics Corp. (BCTX) | 2025-07-31 | $21.27M | -21.7% |
| Immunic, Inc. (IMUX) | 2025-12-31 | $81.98M | +2.4% |
| Rein Therapeutics, Inc. (RNTX) | 2025-12-31 | $11.03M | -22.6% |
| Phio Pharmaceuticals Corp. (PHIO) | 2025-12-31 | $4.62M | +26.8% |
| Kiora Pharmaceuticals Inc (KPRX) | 2025-12-31 | $10.78M | +37.5% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $313.0K | -52.4% |
Compare GANX, CRVO, MBRX, BCTX side by side · Screen every company in Pharmaceutical Preparations ↗